Colorectal cancer

67 trials 36 recruiting MedDRA PT
67 Registered trials
36 Recruiting
46 Unique sponsors
55 Unique IMPs
55 Commercial trials
Drug classes (ATC)
— ATC code not specified 44
L Oncology (ATC L) 18
V Various (ATC V) 4
S Ophthalmology/ENT (ATC S) 1
B Haematology (ATC B) 1
A Gastroenterology (ATC A) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 25 substances
Kinase inhibitor 4 substances
Monoclonal antibody 3 substances
Monoclonal antibody (human) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Antimetabolite 2 substances
Antibody-drug conjugate (ADC) 2 substances
Monoclonal antibody (tumor, humanized) 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Monoclonal antibody (chimeric) 1 substance
Supportive / rescue 1 substance
Topoisomerase I inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Anthracycline 1 substance
Taxane 1 substance
CDK inhibitor 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
PARP inhibitor 1 substance
Supportive / diluent 1 substance
Phase III: 6 Phase II/III: 1 Phase II: 17 Phase I/II: 9 Phase III/IV: 1 Phase IV: 2 Phase I: 22 Phase I (Other): 3 Phase I (First in Human): 6

Filter these 67 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 67 trials

Phase III

6 trials
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting
  • Janssen - Cilag International Commercial
    AMIVANTAMAB; CETUXIMAB
    2024-513852-13-00 9 countries 2025 n=266
    Recruiting
  • Janssen - Cilag International Commercial
    AMIVANTAMAB; BEVACIZUMAB; CETUXIMAB
    2024-513853-66-00 10 countries 2025 n=162
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB
    2025-524160-38-00 10 countries 2026 n=37
    Recruiting
  • Pfizer Inc. Commercial
    BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN
    2023-509405-77-00 13 countries 2021 n=300
    Ended
  • Institut Gustave Roussy Academic
    SODIUM CHLORIDE; TISLELIZUMAB
    2023-503316-33-00 1 country 2024 n=717
    Recruiting

Phase II/III

1 trial
  • The University Of Birmingham Academic
    CAPECITABINE
    2024-516106-31-00 3 countries 2017 n=230
    Ended

Phase II

17 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    TELISOTUZUMAB ADIZUTECAN
    2023-505110-14-00 3 countries 2024 n=61
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    TELISOTUZUMAB ADIZUTECAN
    2024-518015-19-00 4 countries 2025 n=24
    Recruiting
  • AstraZeneca AB Commercial
    VOLRUSTOMIG
    2024-518469-84-00 5 countries 2025 n=69
    Recruiting
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Blue Earth Diagnostics Ireland Limited Commercial
    GA68-ONCOFAP
    2025-521983-36-00 2 countries n=65
    Pending
  • Bristol Myers Squibb International Corporation Commercial
    DARATUMUMAB; IPILIMUMAB; NIVOLUMAB; RELATLIMAB
    2024-516004-42-01 2 countries 2014 n=143
    Ended
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting
  • Leap Therapeutics Inc. Commercial
    BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN; SIREXATAMAB
    2022-501465-40-00 1 country 2023 n=25
    Ended
  • Ono Pharmaceutical Co. Ltd. Commercial
    4-[4-CYANO-2-[[(1'R,4S)-6-(PROPAN-2-YLCARBAMOYL)SPIRO[2,3-DIHYDROCHROMENE-4,2'-CYCLOPROPANE]-1'-CARBONYL]AMINO]PHENYL]BUTANOIC ACID; NIVOLUMAB
    2024-519590-19-00 3 countries 2025 n=76
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2024-512119-34-00 12 countries 2022 n=75
    Recruiting
  • TargED Biopharmaceuticals B.V. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
    2025-521730-28-00 5 countries 2026 n=54
    Recruiting
  • AIO-Studien gGmbH Academic
    ATEZOLIZUMAB; MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
    2024-515224-37-00 1 country 2023 n=80
    Ended
  • Fondation Franc.Cancerologie Digestive Academic
    FLUOROURACIL; FOLINIC ACID; PANITUMUMAB
    2024-514030-20-00 4 countries 2025 n=37
    Recruiting
  • Grupo Espanol Multidisciplinar En Cancer Digestivo Academic
    OLAPARIB; PEMBROLIZUMAB
    2023-509095-42-00 1 country 2022 n=40
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    ATEZOLIZUMAB; BEVACIZUMAB
    2024-517119-59-00 1 country 2019 n=38
    Recruiting
  • Institut De Cancerologie De L Ouest Academic
    BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; PANITUMUMAB
    2024-514560-10-00 1 country 2025 n=114
    Recruiting
  • Odense University Hospital Academic
    IMP not specified
    2025-521941-25-00 1 country n=165
    Pending

Phase I/II

9 trials
  • BioNTech SE Commercial
    BNT314; BNT327; PUMITAMIG
    2025-521768-36-00 2 countries 2026 n=168
    Recruiting
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB
    2023-503554-12-00 5 countries 2019 n=96
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Eisai Limited Commercial
    (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE; LENVATINIB; PEMBROLIZUMAB
    2023-505425-14-00 1 country 2022 n=30
    Ended
  • Eisai Limited Commercial
    (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE; DOXORUBICIN HYDROCHLORIDE; LENVATINIB; PACLITAXEL
    2023-510275-64-00 4 countries 2023 n=83
    Recruiting
  • Janssen - Cilag International Commercial
    AMIVANTAMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN
    2023-506517-22-00 4 countries 2022 n=37
    Recruiting
  • Novartis Pharma AG Commercial
    1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZOL-5-YL)-1H -PYRAZOL-1-YL]-2-AZASPIRO[3.3]HEPTAN-2-YL}PROP-2-EN-1-ONE; RIBOCICLIB; TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE
    2023-506716-41-00 5 countries 2023 n=200
    Recruiting
  • Revolution Medicines Inc. Commercial
    IMP not specified
    2023-508178-27-00 5 countries 2024 n=300
    Recruiting
  • AIO-Studien gGmbH Academic
    METHADONE HYDROCHLORIDE
    2024-519509-37-00 1 country 2025 n=84
    Ended

Phase III/IV

1 trial
  • Centre Hospitalier Universitaire Rouen Academic
    INDOCYANINE GREEN
    2024-515118-42-00 1 country 2024 n=1,010
    Recruiting

Phase IV

2 trials
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    SIMETICONE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM CITRATE, SODIUM SULFATE ANHYDROUS, MACROGOL 4000, CITRIC ACID; SODIUM PICOSULFATE, MAGNESIUM OXIDE, LIGHT, CITRIC ACID
    2025-523748-11-00 1 country 2026 n=818
    Recruiting
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana Academic
    IMP not specified
    2024-514790-22-00 1 country n=174
    Pending

Phase I

22 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-509335-60-00 4 countries 2023 n=177
    Recruiting
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • Amgen Inc. Commercial
    IMP not specified
    2025-521707-48-00 7 countries 2025 n=135
    Recruiting
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-514704-13-00 1 country n=30
    Ended
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-511744-27-00 2 countries 2022 n=240
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2024-515617-18-00 5 countries 2022 n=140
    Ended
  • Fusion Pharmaceuticals Inc. Commercial
    IMP not specified
    2025-521235-37-00 1 country n=45
    Ended
  • IGM Biosciences Inc. Commercial
    IMP not specified
    2023-504545-31-00 2 countries 2023 n=22
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-516526-66-00 1 country 2025 n=80
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2025-521535-36-00 1 country 2025 n=52
    Recruiting
  • Kura Oncology Inc. Commercial
    IMP not specified
    2024-513285-19-00 4 countries 2025 n=66
    Recruiting
  • Molecure S.A. Commercial
    IMP not specified
    2024-510836-31-00 1 country 2023 n=40
    Recruiting
  • NEOGAP Therapeutics AB Commercial
    IMP not specified
    2024-512296-13-00 1 country 2023 n=16
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510356-23-00 6 countries 2025 n=76
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521702-18-00 5 countries 2026 n=62
    Recruiting
  • One-carbon Therapeutics AB Commercial
    IMP not specified
    2024-519639-40-00 2 countries 2025 n=33
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2024-517988-23-00 2 countries n=61
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505858-18-00 4 countries 2024 n=175
    Halted
  • Valo Therapeutics Oy Commercial
    IMP not specified
    2024-517580-23-00 2 countries 2023 n=23
    Ended

Phase I (Other)

3 trials
  • Molecure S.A. Commercial
    IMP not specified
    2024-513006-61-00 1 country 2023 n=30
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510379-77-00 1 country 2020 n=35
    Ended
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended

Phase I (First in Human)

6 trials
  • Crescent Biopharma Inc. Commercial
    CR-001
    2025-523590-42-00 1 country n=44
    Pending
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Ipsen Pharma Commercial
    IPN01194
    2023-506228-10-00 2 countries 2024 n=36
    Ended
  • ITM Oncologics GmbH Commercial
    177LU-DPI-4452; 68GA-DPI-4452; ACETAZOLAMIDE
    2023-504254-35-00 2 countries 2023 n=97
    Recruiting
  • Novartis Pharma AG Commercial
    1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZOL-5-YL)-1H -PYRAZOL-1-YL]-2-AZASPIRO[3.3]HEPTAN-2-YL}PROP-2-EN-1-ONE; BATOPROTAFIB; TISLELIZUMAB
    2023-508073-87-00 7 countries 2024 n=359
    Ended
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 6 Phase I, Phase I (Other), Phase I (First in Human), Phase I/II 3
Janssen - Cilag International Commercial 5 Phase I, Phase III, Phase I/II 5
AbbVie Deutschland GmbH & Co. KG Commercial 3 Phase I, Phase II 2
Pfizer Inc. Commercial 3 Phase I, Phase II, Phase III 1
Daiichi Sankyo Inc. Commercial 3 Phase III, Phase I (First in Human), Phase I/II 3
Amgen Inc. Commercial 2 Phase I 1
BeOne Medicines AG Commercial 2 Phase I 1
Molecure S.A. Commercial 2 Phase I, Phase I (Other) 2
Bristol Myers Squibb International Corporation Commercial 2 Phase II, Phase I/II 0
Eisai Limited Commercial 2 Phase I/II 1
AIO-Studien gGmbH Academic 2 Phase II, Phase I/II 0
Beigene Ltd. Commercial 1 Phase I 0
Cullinan Therapeutics Inc. Commercial 1 Phase I 0
Exelixis Inc. Commercial 1 Phase I 0
Fusion Pharmaceuticals Inc. Commercial 1 Phase I 0
IGM Biosciences Inc. Commercial 1 Phase I 0
Kura Oncology Inc. Commercial 1 Phase I 1
NEOGAP Therapeutics AB Commercial 1 Phase I 0
One-carbon Therapeutics AB Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 0
New trials by year
2019
3
2020
1
2021
1
2022
7
2023
12
2024
11
2025
17
2026
6
← All indication landscapes